146 related articles for article (PubMed ID: 38241818)
21. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.
Lenz HJ; Van Cutsem E; Luisa Limon M; Wong KYM; Hendlisz A; Aglietta M; García-Alfonso P; Neyns B; Luppi G; Cardin DB; Dragovich T; Shah U; Abdullaev S; Gricar J; Ledeine JM; Overman MJ; Lonardi S
J Clin Oncol; 2022 Jan; 40(2):161-170. PubMed ID: 34637336
[TBL] [Abstract][Full Text] [Related]
22. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022.
André T; Cohen R; Salem ME
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834
[TBL] [Abstract][Full Text] [Related]
23. AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
Antoniotti C; Borelli B; Rossini D; Pietrantonio F; Morano F; Salvatore L; Lonardi S; Marmorino F; Tamberi S; Corallo S; Tortora G; Bergamo F; Brunella DS; Boccaccino A; Grassi E; Racca P; Tamburini E; Aprile G; Moretto R; Boni L; Falcone A; Cremolini C
BMC Cancer; 2020 Jul; 20(1):683. PubMed ID: 32698790
[TBL] [Abstract][Full Text] [Related]
24. Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer.
Ambrosini M; Rousseau B; Manca P; Artz O; Marabelle A; André T; Maddalena G; Mazzoli G; Intini R; Cohen R; Cercek A; Segal NH; Saltz L; Varghese AM; Yaeger R; Nusrat M; Goldberg Z; Ku GY; El Dika I; Margalit O; Grinshpun A; Kasi P; Schilsky R; Lutfi A; Shacham-Shmueli E; Khan Afghan M; Weiss L; Westphalen CB; Conca V; Decker B; Randon G; Elez E; Fakih M; Schrock AB; Cremolini C; Jayachandran P; Overman MJ; Lonardi S; Pietrantonio F
Ann Oncol; 2024 May; ():. PubMed ID: 38777726
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer.
Mazzoli G; Cohen R; Lonardi S; Corti F; Elez E; Fakih M; Jayachandran P; Colle R; Shah AT; Salati M; Fenocchio E; Salvatore L; Ambrosini M; Ros J; Intini R; Cremolini C; Overman MJ; André T; Pietrantonio F
Eur J Cancer; 2022 Sep; 172():171-181. PubMed ID: 35777274
[TBL] [Abstract][Full Text] [Related]
26. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A
Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer.
Martin-Romano P; Ammari S; El-Dakdoukti Y; Baldini C; Varga A; Vuagnat P; Angevin E; Bahleda R; Gazzah A; Champiat S; Michot JM; Postel-Vinay S; Marabelle A; Soria JC; Boige V; Malka D; Ducreux M; Massard C; Hollebecque A
Eur J Cancer; 2020 Sep; 137():117-126. PubMed ID: 32755794
[TBL] [Abstract][Full Text] [Related]
28. Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer.
Nasca V; Barretta F; Corti F; Lonardi S; Niger M; Elez ME; Fakih M; Jayachandran P; Shah AT; Salati M; Fenocchio E; Salvatore L; Cremolini C; Ros J; Ambrosini M; Mazzoli G; Intini R; Overman MJ; Miceli R; Pietrantonio F
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36593068
[TBL] [Abstract][Full Text] [Related]
29. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.
André T; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Abdullaev S; Memaj A; Lei M; Dixon M; Kopetz S; Overman MJ
Ann Oncol; 2022 Oct; 33(10):1052-1060. PubMed ID: 35764271
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of immune-checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta-analysis.
Kundel Y; Sternschuss M; Moore A; Perl G; Brenner B; Goldvaser H
Cancer Med; 2020 Oct; 9(20):7613-7625. PubMed ID: 32869544
[TBL] [Abstract][Full Text] [Related]
31. Adrenal gland as a sanctuary site for immunotherapy in patients with microsatellite instability-high metastatic colorectal cancer.
Cohen R; Jonchère V; De La Fouchardière C; Ratovomanana T; Letourneur Q; Ayadi M; Armenoult L; Buisson A; Sarabi M; Pellat A; Colle R; Paye F; Meeus P; Svrcek M; Duval A; Andre T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579738
[TBL] [Abstract][Full Text] [Related]
32. Imaging-guided prognostic score-based approach to assess the benefits of combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic MSI-H colorectal cancer patients.
Barbe R; Belkouchi Y; Menu Y; Cohen R; David C; Kind M; Harguem S; Dawi L; Hadchiti J; Selhane F; Billet N; Ammari S; Bertin A; Lawrance L; Cervantes B; Hollebecque A; Balleyguier C; Cournede PH; Talbot H; Lassau N; Andre T
Eur J Cancer; 2024 May; 202():114020. PubMed ID: 38502988
[TBL] [Abstract][Full Text] [Related]
33. Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors.
Gallois C; Landi M; Taieb J; Sroussi M; Saberzadeh-Ardestani B; Cazelles A; Lonardi S; Bergamo F; Intini R; Maddalena G; Pietrantonio F; Corti F; Ambrosini M; Martinetti A; Germani MM; Boccaccio C; Vetere G; Mouillet-Richard S; de Reynies A; Sinicrope FA; Cremolini C; Laurent-Puig P
Clin Cancer Res; 2023 Sep; 29(18):3771-3778. PubMed ID: 37439810
[TBL] [Abstract][Full Text] [Related]
34. Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Chen EX; Loree JM; Titmuss E; Jonker DJ; Kennecke HF; Berry S; Couture F; Ahmad CE; Goffin JR; Kavan P; Harb M; Colwell B; Samimi S; Samson B; Abbas T; Aucoin N; Aubin F; Koski S; Wei AC; Tu D; O'Callaghan CJ
JAMA Netw Open; 2023 Dec; 6(12):e2346094. PubMed ID: 38051531
[TBL] [Abstract][Full Text] [Related]
35. Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial.
Taïeb J; André T; El Hajbi F; Barbier E; Toullec C; Kim S; Bouche O; Di Fiore F; Chauvenet M; Perrier H; Evesque L; Laurent-Puig P; Emile JF; Bez J; Lepage C; Tougeron D
Dig Liver Dis; 2021 Mar; 53(3):318-323. PubMed ID: 33359404
[TBL] [Abstract][Full Text] [Related]
36. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA;
N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544
[TBL] [Abstract][Full Text] [Related]
37. Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers: A Systematic Review and Meta-analysis.
Petrelli F; Ghidini M; Ghidini A; Tomasello G
JAMA Oncol; 2020 Jul; 6(7):1068-1071. PubMed ID: 32407439
[TBL] [Abstract][Full Text] [Related]
38. Complete Metabolic Response to Combined Immune Checkpoint Inhibition after Progression of Metastatic Colorectal Cancer on Pembrolizumab: A Case Report.
Krekeler C; Wethmar K; Mikesch JH; Kerkhoff A; Menck K; Lenz G; Schildhaus HU; Wessolly M; Hoffmann MW; Pascher A; Asmus I; Wardelmann E; Bleckmann A
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569431
[TBL] [Abstract][Full Text] [Related]
39. How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation.
Wang Q; Shen X; Chen G; Du J
Int J Cancer; 2023 Aug; 153(4):709-722. PubMed ID: 36752642
[TBL] [Abstract][Full Text] [Related]
40. Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer.
Morse MA; Overman MJ; Hartman L; Khoukaz T; Brutcher E; Lenz HJ; Atasoy A; Shangguan T; Zhao H; El-Rayes B
Oncologist; 2019 Nov; 24(11):1453-1461. PubMed ID: 31147488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
